It is a New Zealand-based biomedical company specialising in soft tissue regeneration. It develops, manufactures, and distributes medical and surgical products.

The company's principal market is the United States, where it markets four key products: 

• Endoform
• Myriad
• OviTex
• Symphony

These products improve healing in complex wounds and soft tissue reconstruction. 

It appears Bell Potter sees significant upside in this ASX small-cap stock on the back of positive 1H26 earnings. 

The broker has a buy recommendation and optimistic price target, suggesting more than 20% upside. 

What did the company report?

On Tuesday, Aroa Biosurgery released H1 FY26 Results. 

This included: 

• Total revenue of NZ$44.9 million (14% growth on H1 FY25)
• NZ$19.7 million in Myriad product revenue (33% growth on H1 FY25)
• NZ$19.2 million in total OviTex/OviTex PRSi product revenue (4% growth on FY25)
• Product gross margin of 85%
• Normalised EBITDA profit of NZ$1.8 million (up from NZ$1.5 million normalised EBITDA loss in H1 FY25)

FY26 Outlook

• Revenue of NZ$92-$100 million (10%-20% growth on FY25 on a constant currency basis)
• Normalised EBITDA of NZ$5-$8 million (19%-90% growth on FY25)

Commenting on AROA's H1 FY26 results, Managing Director and CEO Brian Ward said:

We are very pleased with our first half performance, delivering NZ$44.9 million in total revenue, underpinned by strong Myriad growth, and our fourth consecutive quarter of positive operating cash flow.

We reaffirm our FY26 guidance of NZ$92–100 million in revenue and NZ$5–8 million normalised EBITDA. Looking ahead to the second half of FY26, we expect new clinical publications to further validate AROA ECM's efficacy and strengthen its commercial uptake.

Reason for optimism for this ASX small-cap stock

Markets reacted positively to the results of Aroa Biosurgery yesterday. 

The stock price closed almost 8% higher at $0.68. 

Following the results, Bell Potter said ARX's balance sheet continues to strengthen. 

We are confident regarding the ongoing performance of the Myriad sales team, while conviction levels surrounding the Tela Bio group are lower. Fortunately 2H is traditionally the stronger sales period for Tela.

The broker has a buy recommendation on this ASX small-cap stock and a price target of $0.85. 

From yesterday's closing price, this indicates an upside of 25%. 

Elsewhere, TradingView has a 12-month price target of $0.845 and online brokerage platform Selfwealth lists the ASX small-cap stock as undervalued by approximately 30%.

The post This ASX small-cap stock could be set to rise 25% appeared first on The Motley Fool Australia.

That's because analysts at Bell Potter have named the two small cap ASX shares listed below as buys with potential to deliver outsized returns.

Let's see what the broker is saying about them:

Aroa Biosurgery Ltd (ASX: ARX)

The first small cap ASX share that Bell Potter is tipping as a buy is Aroa Biosurgery.

It is a commercial stage medical device company that operates within the complex wound care and soft tissue reconstruction sector.

The broker highlights that Aroa Biosurgery is well-placed to deliver earnings growth and strong free cash flow generation in the coming years. This is despite a product launch delay. It said:

The FY26 revenue forecast is reduced from $109m to $103m – modestly above the top end of guidance range. FY27 revenues also reduced due to the delay in launch of the Symphony product. We also expect FY26 EBITDA at the upper end of guidance. Over the forecast period we expect meaningful growth in earnings and FCF driven by leverage to the 85% gross margin. ARX is currently trading on an EV/FY25 revenue multiple of ~1.9x relative to our valuation benchmark of 3.0x.

Bell Potter has a buy rating and 85 cents price target on the company's shares. Based on its current share price of 51 cents, this suggests that upside of 66% is possible between now and this time next years.

Integral Diagnostics Ltd (ASX: IDX)

Another small cap ASX share that could be a buy according to the broker is Integral Diagnostics.

It is a leading diagnostic imaging company that merged with Capitol Health. It operates 151 clinics throughout Australia, offering a range of imaging modalities through its clinics.

Bell Potter believes that the small cap could be positioned for a period of double-digit earnings growth. It explains:

We have adjusted our blended valuation for the rebased earnings and given the proximity to the FY25 reporting season, rolled forward our DCF and EBITDA multiple valuations to arrive at a c.1.7% upgrade to our TP to $3.65/sh, or c.50% upside to the current share price. We think IDX is emerging with several tailwinds that could support double-digit earnings growth and support a re-rating of the company's valuation.

Bell Potter has a buy rating and $3.65 price target on its shares. This implies potential upside of 50% for investors over the next 12 months.

The post These small cap ASX shares could rise 50% to 65% appeared first on The Motley Fool Australia.

In afternoon trade, the benchmark ASX 200 index is up 0.25%.

While this is positive, it pales in comparison to what one small cap ASX share is recording today.

Which small cap ASX share?

The small cap in question is Aroa Biosurgery Ltd (ASX: ARX). It is a soft-tissue regeneration company with a mission to unlock regenerative healing for everybody.

It develops, manufactures, sells, and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction.

At the time of writing, its shares are up 10% to 52 cents after investors responded positively to the release of its full year results.

According to the release, the company recorded a 23% increase in total revenue to NZ$84.7 million. This was ahead of its guidance range of NZ$81 million to NZ$84 million.

The drivers of its growth were its Myriad product and OviTex product. Myriad product revenue was up 38% to NZ$32.3 million and OviTex product revenue was up 22% to NZ$39.7 million.

And with a product gross margin of 86%, the small cap ASX share posted normalised EBITDA of NZ$4.2 million for the year. This is up from a NZ$3.2 million loss a year ago. Once again, this exceeds its guidance for FY 2025, which was NZ$2 million to NZ$4 million.

More good news is that Aroa Biosurgery achieved positive operating cash flow the second half. This led to it finishing the period with a cash balance of NZ$22 million and no debt.

Outlook

Also likely to be going down well with the market is management's guidance for FY 2026.

It is expecting its strong form to continue and is forecasting revenue of NZ$92 million to NZ$100 million and normalised EBITDA of NZ$5 million to NZ$8 million. This represents growth of 10% to 20% on the top line and 19% to 90% for its earnings.

Commenting on the year ahead, the small cap ASX share's managing director and CEO, Brian Ward, said:

FY25 marks a significant financial milestone – our first year of normalised EBITDA profitability since listing. Looking ahead, we are increasingly confident about our ability to deliver strong top-line growth and enhanced profitability in FY26 and beyond. Myriad clearly demonstrates that we are delivering on our vision to unlock regenerative healing for everybody.

The post Which small cap ASX share is jumping 10% on strong results appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Accent Group Ltd (ASX: AX1)

The Accent share price is down 3% to $2.31. This follows the release of a first half trading update from the footwear retailer this morning. According to the release, the company expects to report group EBIT of approximately $80 million for the half. This includes a positive net impact of $3.3 million relating to non-recurring items and will be up from $72.4 million in the prior corresponding period. Total group owned sales were up 4.6% for the half, with like for like sales up 2.9%. However, it notes that its like for like sales growth softened late in the year.

Aroa Biosurgery Ltd (ASX: ARX)

The Aroa Biosurgery share price is down 21% to 63.5 cents. Investors have been selling this medical device company's shares following the release of its quarterly update. Aroa Biosurgery reported cash receipts from customers of NZ$19.5 million, which was in line with its expectations. Looking ahead, management is guiding to total revenue of NZ$81 million to NZ$84 million in FY 2025. This represents a 17% to 22% increase on FY 2024's revenue. A normalised EBITDA profit of NZ$2 million to NZ$4 million is also expected.

Playside Studios Ltd (ASX: PLY)

The Playside Studios share price is down 47% to 20 cents. This follows the release of a disappointing half year update from the video game developer. Playside Studios reported a 21% decline in revenue to $28.5 million and an EBITDA loss of $2.8 million for the half. The latter is down from a $12.2 million EBITDA profit a year ago. Management has also downgraded its guidance for FY 2025. Revenue in FY 2025 is now expected to be $50 million to $54 million (previously $62 million to $68 million) and EBITDA is expected to be a loss of $6 million to $10 million (previously a profit of $0 million to $5 million).

Premier Investments Ltd (ASX: PMV)

The Premier Investments share price is down 22% to $22.29. This has been driven by the retail conglomerate's shares going ex-distribution today. As part of the merger of its Apparel Brands business with Myer Holdings Ltd (ASX: MYR), the company has been issued 890.5 million new shares in the department store operator. Together with its existing shareholding, Premier Investments is distributing a total of 1,151.5 million Myer shares to eligible shareholders through an in-specie distribution. This will take place on 6 February 2025.

The post Why Accent, Aroa, Playside, and Premier Investments shares are tumbling today appeared first on The Motley Fool Australia.

That's because the potential returns on offer at the small end of the market can be material. Though, it is always worth remembering that this greater reward brings greater risk.

With that in mind, let's take a look at two small cap ASX stocks that have recently been named as buys and tipped to rise strongly from current levels. Here's what you need to know about them:

Aroa Biosurgery Ltd (ASX: ARX)

This morning, Bell Potter reiterated its buy rating on small cap ASX stock Aroa Biosurgery.

It is a wound repair specialist company that uses a decellularised extra cellular matrix derived from ovine (sheep) gut.

Bell Potter has been impressed with the company's performance in FY 2024 and expects more of the same in FY 2025. Despite this, it trades at a discount to peers. The broker explains:

ARX is likely to deliver strong double digit percentage growth in FY25 and it is trading at a heavy discount to peers. Other than earnings, important catalysts include the headline data from pending scientific papers regarding the ongoing MASTRR study for Myriad in the treatment of trauma, limb salvage and colorectal surgery. The investment in these studies has been significant and we believe will have a long shelf life. The sales force is now well established and poised to take advantage of these important data releases.

Bell Potter has put a buy rating and 90 cents price target on its shares. This suggests that upside of 30% is possible over the next 12 months.

Camplify Holdings Ltd (ASX: CHL)

A second ASX small cap stock that has been given the thumbs up by analysts this month is Camplify.

It operates one of the world's leading peer-to-peer digital marketplace platforms, connecting recreational vehicle (RV) owners to hirers. It has operations in Australia, New Zealand, Spain, the UK, Germany, Austria and Netherlands.

Morgans continues to believe that the market is thoroughly undervaluing the company's shares. It likes Camplify due to its positive long term growth outlook, which is being underpinned by its large opportunity both at home and abroad. The broker recently said:

We expect CHL to continue to grow into its large addressable market locally, with over 790k registered RVs in Australia and ~130k in NZ. CHL only has ~2% of these on its platform. It has broadly doubled its domestic fleet since listing and with its acquisition of Germany- based PaulCamper (PC) now has a total fleet of over 29,000, making it a true global player.

Morgans has just put an add rating and $2.10 price target on its shares. This is more than double where they trade today.

The post 2 small cap ASX stocks with big price targets appeared first on The Motley Fool Australia.

But which small caps could be top options for investors in September? Let's take a look at two that could be worth considering:

Aroa Biosurgery Ltd (ASX: ARX)

Bell Potter thinks that Aroa Biosurgery could be a small cap ASX stock to buy.

It is a medical device company focused on wound repair. It uses a decellularised extra cellular matrix derived from ovine (sheep) gut for wound healing and soft tissue reconstruction.

The broker believes the company could be well-placed for growth over the coming years thanks to growing demand for its technology. It said:

The Myriad product achieved the highest rate of revenue growth in FY24. It is applied in the surgical setting to provide a substrate for regeneration of soft tissue and for reconstructive surgery. In FY24 revenues grew by 75% to NZ$23.3m and we expect a similar growth rate in FY25 and FY26 driven by an expanded user base and data from the Myriad Augmented Soft Tissue Regeneration Registry (MASTRR). ARX also expects to report data from its 120 patient randomised clinical trial in diabetic foot ulcer patients. The trial is investigating the healing properties of the Symphony product. Earlier studies in a very difficult patient population with advanced DFU's provided highly supportive data on the rate of wound healing.

Bell Potter has a buy rating and 90 cents price target on its shares. This implies potential upside of approximately 70% for investors from current levels.

Camplify Holdings Ltd (ASX: CHL)

Another ASX small cap stock that has been given the thumbs up Camplify.

It operates one of the world's leading peer-to-peer digital marketplace platforms, connecting recreational vehicle (RV) owners to hirers. It has operations in Australia, New Zealand, Spain, the UK, Germany, Austria and Netherlands.

Analysts at Morgans are feeling very positive about the company's long term growth outlook thanks to opportunity both at home and abroad. They explain:

We expect CHL to continue to grow into its large addressable market locally, with over 790k registered RVs in Australia and ~130k in NZ. CHL only has ~2% of these on its platform. It has broadly doubled its domestic fleet since listing and with its acquisition of Germany- based PaulCamper (PC) now has a total fleet of over 29,000, making it a true global player.

Morgans has an add rating and $2.55 price target on its shares. This is more than double where its shares are currently trading.

The post Experts name 2 small cap ASX stocks to buy for big returns appeared first on The Motley Fool Australia.

After all, the potential returns on offer at the small end of the market can be significant. Though, it is always worth remembering with this greater reward, comes greater risk.

With that in mind, let's take a look at three small cap ASX stocks that have been tipped to rise strongly from current levels. Here's what you need to know about them:

Aroa Biosurgery Ltd (ASX: ARX)

Analysts at Bell Potter think that Aroa Biosurgery could be a small cap ASX stock to buy right now.

It is a wound repair specialist company that uses a decellularised extra cellular matrix derived from ovine (sheep) gut.

Bell Potter has been impressed with the company's performance in FY 2024 and expects more of the same in the coming years. It explains:

The Myriad product achieved the highest rate of revenue growth in FY24. It is applied in the surgical setting to provide a substrate for regeneration of soft tissue and for reconstructive surgery. In FY24 revenues grew by 75% to NZ$23.3m and we expect a similar growth rate in FY25 and FY26 driven by an expanded user base and data from the Myriad Augmented Soft Tissue Regeneration Registry (MASTRR). ARX also expects to report data from its 120 patient randomised clinical trial in diabetic foot ulcer patients. The trial is investigating the healing properties of the Symphony product. Earlier studies in a very difficult patient population with advanced DFU's provided highly supportive data on the rate of wound healing.

Bell Potter has a buy rating and 90 cents price target on its shares. This suggests that upside of 42% is possible over the next 12 months.

Camplify Holdings Ltd (ASX: CHL)

Another ASX small cap share that has been named as a buy is Camplify. It is the number one player in ANZ in the peer-to-peer RV rental space.

Morgans is a fan of the company due to its huge growth opportunity at home and abroad. It explains:

We expect CHL to continue to grow into its large addressable market locally, with over 790k registered RVs in Australia and ~130k in NZ. CHL only has ~2% of these on its platform. It has broadly doubled its domestic fleet since listing and with its acquisition of Germany- based PaulCamper (PC) now has a total fleet of over 29,000, making it a true global player.

The broker has an add rating and $2.55 price target on its shares. This implies potential upside of over 100% for investors.

Mach7 Technologies Ltd (ASX: M7T)

A third small cap ASX share that has been named as a buy is Mach7. It is an enterprise image management systems provider.

Morgans is feeling positive about the company's outlook and is forecasting strong revenue growth in the coming years. It said:

Mach7 is a provider of enterprise image management systems that allow hospitals to identify, connect and share image and patient care data. Revenue growth of at least 20% pa is expected over the next three years.

The broker has an add rating and a $1.56 price target on its shares. This suggests that its shares could more than double in value from current levels.

The post 3 small cap ASX stocks that could rise 40% to 100%+ appeared first on The Motley Fool Australia.

They have just been tipped as Bell Potter's top healthcare stocks to buy now:

Aroa Biosurgery Ltd (ASX: ARX)

Aroa Biosurgery describes itself as a soft-tissue regeneration company committed to unlocking regenerative healing for everybody.

Bell Potter is feeling very positive about the company's outlook and has put a buy rating and 90 cents price target on its shares. It is expecting the ASX healthcare stock's strong top line growth to continue in FY 2025 and FY 2026. It said:

In FY24 revenues grew by 75% to NZ$23.3m and we expect a similar growth rate in FY25 and FY26 driven by an expanded user base and data from the Myriad Augmented Soft Tissue Regeneration Registry (MASTRR). ARX also expects to report data from its 120 patient randomised clinical trial in diabetic foot ulcer patients. The trial is investigating the healing properties of the Symphony product. Earlier studies in a very difficult patient population with advanced DFU's provided highly supportive data on the rate of wound healing.

Cyclopharm Ltd (ASX: CYC)

Bell Potter is also bullish on this global radiopharmaceutical company which has a focus on pulmonary care. Especially given its strong balance sheet following a recent capital raising.

The broker currently has a buy rating and $3.40 price target on the ASX healthcare stock. It said:

Cyclopharm recently completed a $24m capital raise with funds to provide working capital to support the expanding revenue base in the US. Since receiving FDA approval for Technegas in the US in September 2023, CYC has notched up numerous firsts including contract signings and first revenues earned. […] The company estimates the US market for Technegas at US$180m annually inclusive of US$90m being the initial market for diagnosis of pulmonary embolism (PE) which it believes it can win within 5 to 7 years from launch. The second stage of the market also relates to PE where the company believes it can win market share in those patients currently diagnosed via CT.

Telix Pharmaceuticals Ltd (ASX: TLX)

Finally, another radiopharmaceutical company that could be a buy according to Bell Potter is Telix. It has a buy rating and $19.00 price target on its shares.

Bell Potter likes the company due to its revenue-generating Illuccix product, as well as its promising product pipeline. The broker explains:

The fundamental drivers of value remain firmly in place, including: revenues from the sale of Illuccix continue to grow; recently completed submission of the Biological license application for Zircaix in early June; and additional catalysts including submission of the New Drug Application for Pixclara, commencement of enrolment in the prostate cancer therapy and initial data from the STARLITE trial.

The post Bell Potter names the best ASX healthcare stocks to buy in FY25 appeared first on The Motley Fool Australia.

That's because analysts at Bell Potter believe the small cap ASX stock could rise materially from current levels.

What is this small cap ASX stock?

Aroa Biosurgery is a soft-tissue regeneration company. It states that it is committed to "unlocking regenerative healing for everybody."

It develops, manufactures, sells, and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. The small cap ASX stock's products are developed from a proprietary AROA ECM technology platform. It is a novel extracellular matrix biomaterial derived from ovine forestomach.

'A potentially transformational year'

Bell Potter believes that FY 2025 could be a transformational year for the company that could see its first profit and free cash flow. It said:

FY25 is a potentially transformational year for ARX with the likelihood of a maiden profit and positive free cash flows. We believe these have been the drivers of the resurgence in market value of the stock, spurned on by the positive revenue and earnings guidance provided at the recent full year update (for FY24).

Another positive is that there could soon be some clinical trial data available that the broker feels could be supportive of sales. It adds:

While the ARX products appear widely regarded and have been the subject of literally dozens of published articles, the absence of gold standard data from randomised clinical trials is a gap. Recruitment of clinical trials in the key area of lower limb salvage and large trauma wounds is problematic, however, to this end the company has recently completed enrolment of its Myriad Augmented Soft Tissue Regeneration Registry (MASTRR) with clinical data expected to commence in late FY25.

In addition, there's potential for another clinical trial to open up the company to a market with a US$1 billion opportunity. The broker said:

In addition, ARX will shortly complete recruitment of its 120 patient randomised study in diabetic foot ulcer (DFU) patients investigating the wound healing properties of its Symphony product with headline data due in 2H FY25. Data from a recent retrospective real world study is highly supportive of the wound healing properties of Myriad in severe DFU cases. A successful outcome (which we believe is likely) may unlock the market in outpatient wound care for DFU's where TAM is estimated at >US$1.0bn.

Big return potential

This morning, Bell Potter has reiterated its buy rating and 90 cents price target on the small cap ASX stock.

Based on its current share price of 60 cents, this implies potential upside of 50% for investors over the next 12 months.

Overall, this could make Aroa Biosurgery worth a closer look. Particularly if you're looking for some small cap exposure.

The post Guess which small cap ASX stock could rise 50% in a 'transformational year' appeared first on The Motley Fool Australia.

But these three ASX healthcare shares are knocking it out of the park on this otherwise lacklustre day.

Here's why.

Paradigm Biopharmaceuticals Ltd (ASX: PAR)

ASX healthcare share Paradigm Biopharmaceuticals is up 5.88% to 27 cents per share at the time of writing. This follows the release of the company's quarterly activities report. Paradigm revealed a cash balance of $26.2 million as of 31 March, down from $33.5 million on 31 December. Paradigm spent $13.1 million on research and development, down from $27.06 million in the previous quarter. Net cash outflow for the quarter was $6.8 million, which was less than the $8 million to $11 million guidance. The company revised its cash outflow guidance for the June quarter to a range of $7 million to $10 million.

Paradigm shares are down 39% in the year to date. Over the past 12 months, the ASX healthcare share has fallen 72%.

Imugene Ltd (ASX: IMU)

The Imugene share price is up 2.44% to 8.4 cents per share at the time of writing. The clinical-stage immuno‐oncology company has also released its quarterly activities report today. The highlights include a cash or equivalents balance of $114.1 million. Net cash used in operating activities amounted to $25.2 million, with direct research and development costs accounting for 49% of costs.

This ASX healthcare share is down 23% in the year to date. Over the past 12 months, the Imugene share price has fallen 35%.

Aroa Biosurgery Ltd (ASX: ARX)

ASX healthcare share Aroa Biosurgery is currently up 3.09% to 50 cents per share. In its quarterly update today, Aroa reported strong cash receipts from customers of NZ$18 million, reflecting a continued increase in Myriad and OviTex / OviTex PRS sales. There were positive net cash inflows from operations of NZ$300,000, exceeding Q4 breakeven expectations. Net cash outflows from investing activities were down to NZ$700,000, reflecting continued planned investment into additional manufacturing plants and equipment. Completion is expected by Q3 FY25. Aroa booked a 71% reduction in quarterly cash burn to about NZ$1 million, ending the year with a strong closing cash balance of NZ$29.5 million.

Aroa shares are down 39% in the year to date. Over the past 12 months, the ASX healthcare share has dropped 53%.

ASX healthcare shares vs. ASX 200

ASX healthcare stocks have fallen 0.5% in the year to date and are down 5.1% over the past 12 months.

By comparison, the ASX 200 has risen 0.35% in 2023 so far and is up 4.4% over the past year.

The post 3 ASX healthcare shares outperforming on quarterly updates appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

29Metals Ltd (ASX: 29M)

The 29Metals share price is down 11% to 45 cents. Investors appear disappointed by the copper producer's quarterly update. 29Metals reported copper production of 5.2kt for the fourth quarter. This brought its full year production to 18.1kt. Management is guiding to copper production of 18kt to 22kt for 2024.

Aroa Biosurgery Ltd (ASX: ARX)

The Aroa Biosurgery share price is down 9% to 65.25 cents. This follows the release of the medical device company's quarterly update. That update revealed that management has reduced its FY 2024 total revenue guidance to between NZ$67 million and NZ$70 million. This has been driven by a decrease in expected revenue from TELA Bio due to a previous overestimation of Aroa's revenue share on inventory supplied and a delay to a joint product development project.

Mader Group Ltd (ASX: MAD)

The Mader share price is down 6% to $6.26. Investors have been selling this specialist technical services provider's shares despite the release of a solid quarterly update. Mader reported a 31% increase in total revenue to $189.3 million for the second quarter. In addition, the company has reaffirmed its confidence in "delivering FY24 revenue of at least $770m and NPAT of at least $50m."

Netwealth Group Ltd (ASX: NWL)

The Netwealth share price is down 5% to $16.49. This appears to have been driven by a broker note out of Macquarie this morning. According to the note, the broker has downgraded Netwealth's shares to an underperform rating with a $14.80 price target. It notes that Netwealth's quarterly update shows that its growth is continuing to moderate.

The post Why 29Metals, Aroa Biosurgery, Mader, and Netwealth shares are falling appeared first on The Motley Fool Australia.

Four ASX shares that are falling more than most today are listed below. Here's why they are dropping:

Aroa Biosurgery Ltd (ASX: ARX)

The Aroa Biosurgery share price is down 7% to 94 cents. This morning this medical device company released its full-year results. Aroa Biosurgery reported a 55% increase in product revenue to NZ$60.5 million but a loss before tax of NZ$0.9 million. Management is guiding to product revenue of NZ$72 million to NZ$75 million in FY 2024.

Bank of Queensland Ltd (ASX: BOQ)

The Bank of Queensland share price is down 5% to $5.49. This follows news that the regional bank has entered into a voluntary enforceable undertaking with APRA. This will address remediation of weaknesses in the bank's risk management practices, controls, systems, governance and risk culture.

Champion Iron Ltd (ASX: CIA)

The Champion Iron share price is down 2% to $5.98. Investors have been selling this iron ore miner's shares following the release of its full-year results. Champion Iron reported revenue of C$1,395.1 million and EBITDA of C$493.2 million. Goldman Sachs was expecting EBITDA of C$496 million.

Terracom Ltd (ASX: TER)

The Terracom share price is down 6% to 48.5 cents. This morning, this coal miner announced plans to pay a 3 cents per share fully franked dividend for the three months ended 31 March. Investors may have been hoping for a larger dividend given that it has already paid 17.5 cents per share for the first half of FY 2023.

The post Why Aroa Biosurgery, Bank of Queensland, Champion Iron, and Terracom shares are falling appeared first on The Motley Fool Australia.

Here's what it is expecting from these small cap ASX healthcare shares:

Aroa Biosurgery Ltd (ASX: ARX)

The first small cap ASX healthcare share that Morgans is bullish on is Aroa Biosurgery.

The broker highlights that Aroa Biosurgery is a regenerative medicine company engaged in developing, manufacturing, and distributing medical devices for wound and tissue repair. It does this with extracellular matrix (ECM) technology in the United States and internationally.

The company has a range of products. These include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction.

The broker is positive on Aroa Biosurgergy for a number of reasons. These include its low product price point, manufacturing capacity, and product pipeline. It explains:

Aroa has developed a cost effective technology which is estimated to be 30% cheaper than existing products. Sufficient manufacturing capacity through 2 facilities with enough capacity for $100m sales. ARX have a pipeline of new products through both Oroa and TelaBio supported by strong clinical data, we anticipate further news on Symphony and Enivo products.

Morgans currently has an add rating and $1.57 price target on its shares. This implies potential upside of 54% for this small cap ASX healthcare share over the next 12 months.

Volpara Health Technologies Ltd (ASX: VHT)

Another small cap ASX healthcare share that Morgans is tipping as a buy is Volpara.

It is a digital health company offering an increasingly popular solution that improves clinical decision making for early detection of breast cancer. Morgans notes that its products are approved for sale in key regions and provide objective evidence that can be used by relevant specialists including the woman herself to make informed decisions about further screening.

Its analysts have been impressed with the company's performance, which has been underpinned by a strategy shift. It commented:

VHT continues to focus on the most profitable products and markets as well as focusing on larger value customers in line with their revised strategy. The second consecutive quarter of positive net operating cashflow is ahead of management's guidance for 4Q24. We continue to expect the sales pipeline to grow and remain comfortable in guidance to have sufficient cash on hand to maintain net operating cashflow break-even.

Morgans has an add rating and $1.21 price target on this small cap ASX healthcare share. This implies potential upside of 59% for investors over the next 12 month.

The post Morgans says these small cap ASX healthcare shares are buys with 50% upside appeared first on The Motley Fool Australia.

After all, people may cut out dining out or buying a new sofa, but they will still want to remain physically and mentally well.

And with interest rate rises now biting Australian consumers hard, that scenario is well and truly in play.

Here are two ASX shares involved in healthcare that Wilson Asset Management analysts are rating as buys at the moment:

'Momentum is really strong'

The Aroa Biosurgery Ltd (ASX: ARX) has amazingly rocketed almost 46% over the past 12 months, over a time when few non-mining stocks can even claim to be in the black.

Wilson equity dealer William Thompson reckons that trend will continue, calling it a buy.

"It posted a really good sales update in January," Thompson said in a Wilson video.

"They're a New Zealand-based company… They have about seven different products which they're selling in the US."

Aroa Biosurgey is involved in a joint venture with US partner TELA Bio Inc (NASDAQ: TELA), whose reporting next week could prove to be yet another catalyst for the ASX stock.

With a March year end, Aroa's annual result is not far away.

"The momentum is really strong for the company, so it's a buy."

Thompson's peers unanimously agree, with all five analysts surveyed on CMC Markets currently rating Aroa Biosurgery as a buy.

This stock could go anywhere now that supply problems are waning

Resmed CDI (ASX: RMD) has been an old favourite for health investors for decades now, but the share price has struggled in recent times.

Over the past 18 months the stock has lost more than 21% of its value.

According to Wilson equity analyst Anna Milne, the troubles for the business are temporary.

"They've been really struggling to get [computer] chips," she said.

"Now as the broader demand for electronics wanes in this more challenging environment, [Resmed] will find it a lot easier to get these semiconductor chips."

So once that supply problem is fixed, the sky's the limit for the sleep apnoea device market leader.

That's because its nearest rival, Koninklijke Philips NV (AMS: PHIA), was forced out due to a safety recall just under two years ago. 

"With their major competitor Philips still largely out of the market, and will at least be distracted for a few years, we think Resmed is a great company at a fair valuation."

The post Buy these 2 ASX health-tech shares that are ready to rocket: Wilson appeared first on The Motley Fool Australia.

Right now, the All Ordinaries Index is up 0.12%, trading at 7,606.9 points.

Let's take a closer look at four shares trading at their highest point in more than a year today.

4 ASX All Ordinaries shares soaring to 52-week highs

The Stanmore Resources Ltd (ASX: SMR) share price is on the up and up today, gaining 5% at its intraday peak to hit an all-time record high of $3.55.

The coal miner has been on a major roll over the last 12 months, gaining more than 230% in that time.

Joining the coal miner in the green is All Ordinaries biopharmaceutical share Clinuvel Pharmaceuticals Limited (ASX: CUV). It soared 3% earlier today to reach $26.65 – the highest it's been since this time last year.

The last 12 months have been a rollercoaster for the healthcare stock. Six months before it soared to today's high, the stock hit a low of $13.16.

Clinuvel isn't the only All Ordinaries biopharma share posting 52-week highs today.

The share price of Neuren Pharmaceuticals Ltd (ASX: NEU) also surged to a multi-year high of $9.08 earlier today. That marked a 1.6% gain on its previous close.

The last time the stock traded at such levels was in 2007 – before the Global Financial Crisis took hold of markets around the world.

The final ASX All Ordinaries share soaring to long-forgotten highs is Aroa Biosurgery Ltd (ASX: ARX). It surged to $1.20 in afternoon trade – a 1.7% gain on its previous closing price.

The company listed on the ASX following its $45 million initial public offering (IPO) in mid-2020. Investors who got on board in its IPO did so for just 75 cents per share.

The post 4 ASX All Ordinaries shares hitting new 52-week highs today appeared first on The Motley Fool Australia.

Indeed, some gained as much as 9% to surpass the milestone measurement earlier today.

Right now, the All Ords is down 0.13%, trading at 7,378.6 points.

So, what's going right for these All Ords shares on Tuesday? Let's take a look.

5 ASX All Ords shares surpassing 52-week highs today

The A2 Milk Company Ltd (ASX: A2M) share price soared 2.9% to trade at $7.14 at its Tuesday peak – marking a new 18-month high.

Interestingly, there's been no price-sensitive news from the milk and infant formula producer since November.

However, the S&P/ASX 200 Consumer Staples Index (ASX: XSJ) is also outperforming today, gaining 1.52% at the time of writing.

It's also a good day to be invested in All Ords tech share Data#3 Limited (ASX: DTL). The stock soared 9% earlier today to trade at an all-time high of $7.32.

Its surge came on the back of news the IT services and solutions provider expects its first-half pre-tax profits to come in at the high end of its prior guidance.

Data#3 previously flagged between $21 million and $25 million of profits for the period.

Joining its tech peer in posting a new 52-week high today is fellow All Ords share Weebit Nano Ltd (ASX: WBT). The stock rose 3.6% earlier today to reach $4.65 – its highest point in nearly 10 years.

It's now gained a whopping 30% since it announced the tape-out of its 22-nanometre memory chip technology.

The EBOS Group Ltd (ASX: EBO) share price is also at a 10-year high today. In fact, the stock hit its highest point since its 2013 initial public offering (IPO) earlier today when it soared 8.6% to trade at $45.77.

Interestingly, there's been no news from the New Zealand-based healthcare, medical, and pharmaceutical distributor since August.

Finally, fellow All Ords healthcare share Aroa Biosurgery Ltd (ASX: ARX) hit a new 52-week high of $1.19 earlier today. That marked a 3.5% gain today.

It's the seventh time the stock has surpassed the milestone in 2023 so far.

The post 5 ASX All Ords shares cracking new 52-week highs on Tuesday appeared first on The Motley Fool Australia.

Indeed, two are soaring into the green to crack new 52-week highs.

Right now, the All Ords is down 0.2%, trading at 7,137.1 points.

So, which stocks are bucking the trend to reach long-forgotten heights? Let's take a look.

2 All Ords shares trading at 12-month highs

The first All Ords share posting a new 52-week high today is medical device developer Polynovo Ltd (ASX: PNV).

It's soaring 7.83% at the time of writing to trade at $2.48. However, earlier today, it hit $2.50 – marking an 8.7% gain and the highest the stock has been in 18 months.

Interestingly, there's been no news from the healthcare favourite to explain today's rise.

In fact, the last time the market heard price-sensitive news from Polynovo was in mid-December when the company announced the end of a $53 million capital raise – offering new shares for $1.90 apiece.

Thus, those who got in on the raise have already seen a 30% return on investment (ROI).

Joining Polynovo in posting a new 52-week high today is fellow All Ords healthcare share Aroa Biosurgery Ltd (ASX: ARX).

It reached its highest point since October 2021 earlier today, leaping to $1.175 – 2.2% higher than its previous close. It has since slipped slightly to $1.1725, representing a 1.96% gain.

Also, like Polynovo before it, the company hasn't released any news to explain its latest gain.

The last piece of price-sensitive news from Aroa Biosurgery, detailing its half-year performance, dropped in late November.

Then, the company announced its product sales grew 44% year-on-year while its normalised earnings before interest, tax, depreciation, and amortisation (EBITDA) was positive.

The post 2 ASX All Ords shares cracking new 52-week highs on Tuesday appeared first on The Motley Fool Australia.

There are, in fact, companies listed on the ASX right now that are working on sophisticated, market-leading technologies that could one day improve the lives of many around the world.

This week Wilson Asset Management analysts identify two such ASX shares that they recommend as a buy: 

Helping people heal from terrible injuries

ASX biotechnology shares have taken an absolute pummeling over the past 12 months.

But equities dealer Will Thompson is high on Aroa Biosurgery Ltd (ASX: ARX).

"Aroa develops, manufactures and distributes medical products," he said in a WAM video.

"Their product is, with the fear of oversimplifying it, just a really high-quality Band-Aid, which you'd use if you were in a bad motorcycle crash and you lost quite a bit of skin."

The concept itself is mature, but Aroa's product is different from incumbents as it is made organically.

"Next year there's a few regulation changes, which could really benefit it."

In a horrible year for its peers, the Aroa share price is actually 7% higher than where it started 2022. The ASX share has rocketed up an eye-popping 44% since the start of October.

According to Thompson, Aroa has already put some runs on the board.

"It recently posted some storing sales numbers and actually showed that there's some cash generation as well," he said.

"Next year's going to be a big year for them, so it's a buy."

Helping resist global warming

Because of the bearish nature of markets this year, new ASX listings were few and far between.

LGI Ltd (ASX: LGI), which floated in October, is a rare example of a 2022 debutant that isn't in the resources sector.

Thompson explained that LGI is a gas abatement provider.

"Where all your rubbish and landfill goes, they take the methane out of that area," he said.

"Methane's 26 times worse for the environment than carbon dioxide. They turn that into energy, which they supply back into the market."

Therefore the business takes in revenue from both power generation and carbon credits.

"They're doing some really interesting investments where they think they can probably increase profitability by putting a battery in the system. So that's where the capital's going."

The initial public offer saw IGL shares sold at $1.50 per share. The stock closed Thursday at $1.97.

The post Buy 2 ASX shares for cutting-edge tech changing the world: expert appeared first on The Motley Fool Australia.

Polynovo shares fell 3.23% today to $1.98. For perspective, the All Ordinaries Index climbed 0.22% today.

Let's take a look at which share the team at Wilsons recommends.

What do analysts recommend?

Wilsons analysts believe Aroa Biosurgery Ltd  (ASX: ARX) is the "best-value growth wound care on the ASX". Aroa shares soared 10% today.

Following a review of the sector, analysts highlighted they like Aroa's growth outlook and earnings base. In quotes cited by the Financial Review, analysts Dr Shane Storey and Dr Melissa Benson said:

Valuation analysis highlights that ARX's three-year revenue growth outlook is almost identical to PNV, yet it trades at multiples (EV/Revenue, EV/EBITDA) >3 times lower than PNV.

The earnings diversification of Aroa's business provides stability and growth levers that its peers (PNV, Avita Medical Inc (ASX: AVH) do not have afforded to them in the US market.

Aroa highlighted in today's half-year report it is continuing to build its USA sales team. The company has 35 direct US sales representatives.

Revenue lifted 44% on the prior corresponding period to NZ$28.8 million. The company has now upgraded its FY23 revenue guidance from NZ$51-55 million to NZ$62-64 million. The company expects its EBITDA to break even in FY23.

Meanwhile, Polynovo advised today it has received registration approval for its NovoSorb BTM product in Canada. CEO Swami Raote said:

This registration puts us well on our way to accelerating our global impact.

Aroa share price snapshot

The Polynovo share price has soared 28% in the year to date, while Aroa shares have lost 13%.

For perspective, the All Ords has shed 10% in the year to date.

Polynovo has a market capitalisation of nearly $1.3 billion, while Aroa's market cap is $303.3 million.

The post The ASX All Ords share that's a better, cheaper buy than Polynovo: Wilsons appeared first on The Motley Fool Australia.

Four ASX shares that are climbing more than most today are listed below. Here's why they are rising:

Aroa Biosurgery Ltd (ASX: ARX)

The Aroa Biosurgery share price is up 12% to 90 cents. This morning this medical device company released its half year update and revealed a 44% increase in revenue to NZ$28.8 million. In light of this strong half, the soft tissue regeneration company has upgraded its full year guidance for FY 2023 by approximately NZ$10 million.

Cettire Ltd (ASX: CTT)

The Cettire share price is up 12% to $1.74. This is despite there being no news out of the online luxury fashion retailer. This strong gain means its shares have now more than doubled in value since the start of the month. This has been driven by the release of a strong first quarter update earlier this month.

Estia Health Ltd (ASX: EHE)

The Estia Health share price is up 5% to $2.06. This morning this aged care provider announced a deal to acquire four residential aged care homes from the Premier Health Care Group. The release notes that these acquisitions are expected to be earnings per share accretive from the second half of FY 2023.

Weebit Nano Ltd (ASX: WBT)

The Weebit Nano share price is up 4% to $2.44. Investors have been buying this semiconductor company's shares following the release of an investor presentation. The presentation reveals that management believes that the embedded ReRam market will grow from $18 million in 2021 to $957 million by 2027.

The post Why Aroa Biosurgery, Cettire, Estia Health, and Weebit Nano shares are rising appeared first on The Motley Fool Australia.